Author: Ravi Shankar

Transaction led by Frazier Life Sciences with participation from new and existing funds

REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $100 million. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation, working capital and general corporate purposes.

The financing is being led by Frazier Life Sciences and includes participation from new and existing funds.

Morgan Stanley, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Jones are acting as lead managers for the offering. Maxim Group LLC and Lake Street Capital Markets, LLC are acting as co-managers for the offering.

The securities in the registered offering are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-299867), filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2026, and declared effective on November 10, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, New York 10017, or by phone: 1-212-518-9544, or by email: GSEquityProspectusDelivery@guggenheimsecurities.com; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59^th Street, 6^th Floor, New York, New York 10022, or by email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and its authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, Rezolute’s expectations regarding the anticipated use of proceeds and the completion of the offering. The Company’s ability to predict results or the actual effects of its plans or strategies is inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include, among others, those related to market and other financial conditions, satisfaction of customary closing conditions related to the offering, and any other factors discussed in Rezolute’s filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706

Transaction led by Frazier Life Sciences with participation from new and existing funds

REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $100 million. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation, working capital and general corporate purposes.

The financing is being led by Frazier Life Sciences and includes participation from new and existing funds.

Morgan Stanley, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Jones are acting as lead managers for the offering. Maxim Group LLC and Lake Street Capital Markets, LLC are acting as co-managers for the offering.

The securities in the registered offering are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-299867), filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2026, and declared effective on November 10, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8^th Floor, New York, New York 10017, or by phone: 1-212-518-9544, or by email: GSEquityProspectusDelivery@guggenheimsecurities.com; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59^th Street, 6^th Floor, New York, New York 10022, or by email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and its authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, Rezolute’s expectations regarding the anticipated use of proceeds and the completion of the offering. The Company’s ability to predict results or the actual effects of its plans or strategies is inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include, among others, those related to market and other financial conditions, satisfaction of customary closing conditions related to the offering, and any other factors discussed in Rezolute’s filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706

Primary efficacy endpoint achieved based on preliminary results from a November 5^th data evaluation

Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026

REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5^th data evaluation.

The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia. To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants. To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose. Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion. As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression. This participant has been classified as a non-responder for purposes of the primary endpoint. Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.

“We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism,” said Nevan Charles Elam, Founder and Chief Executive Officer of Rezolute. “Notably, these results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program. We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027.”

The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas). Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.

About upLIFT

The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI). Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care. Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension. The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia. Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.

About Tumor Hyperinsulinism

Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor. Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin. A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor. With high morbidity and mortality rates within tumor HI, there remains a significant unmet need for new therapies directed at hypoglycemia treatment. Ersodetug has shown real-world benefit in patients with insulinoma and NICTs.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. 

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. 

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to the potential safety, efficacy and therapeutic and commercial potential of ersodetug for the treatment of hypoglycemia caused by hyperinsulinism; the timing and final results of the Phase 3 upLIFT study of ersodetug in tumor HI, including our expectation to announce full topline results by mid-December 2026; the Company’s plans and expectations regarding a pre-BLA meeting and the potential submission of one or two Biologics License Applications (BLA) for ersodetug for both of tumor HI and congenital HI in 2027; the potential safety, efficacy and therapeutic potential of ersodetug for treating refractory hypoglycemia caused by any form of HI. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. With respect to congenital hyperinsulinism, although FDA has recommended that the Company file a BLA for review for congenital HI after holding a pre-BLA meeting, there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug for congenital HI. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706

Primary efficacy endpoint achieved based on preliminary results from a November 5^th data evaluation

Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026

REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5^th data evaluation.

The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia. To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants. To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose. Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion. As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression. This participant has been classified as a non-responder for purposes of the primary endpoint. Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.

“We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism,” said Nevan Charles Elam, Founder and Chief Executive Officer of Rezolute. “Notably, these results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program. We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027.”

The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas). Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.

About upLIFT

The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI). Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care. Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension. The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia. Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.

About Tumor Hyperinsulinism

Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor. Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin. A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor. With high morbidity and mortality rates within tumor HI, there remains a significant unmet need for new therapies directed at hypoglycemia treatment. Ersodetug has shown real-world benefit in patients with insulinoma and NICTs.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. 

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. 

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to the potential safety, efficacy and therapeutic and commercial potential of ersodetug for the treatment of hypoglycemia caused by hyperinsulinism; the timing and final results of the Phase 3 upLIFT study of ersodetug in tumor HI, including our expectation to announce full topline results by mid-December 2026; the Company’s plans and expectations regarding a pre-BLA meeting and the potential submission of one or two Biologics License Applications (BLA) for ersodetug for both of tumor HI and congenital HI in 2027; the potential safety, efficacy and therapeutic potential of ersodetug for treating refractory hypoglycemia caused by any form of HI. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. With respect to congenital hyperinsulinism, although FDA has recommended that the Company file a BLA for review for congenital HI after holding a pre-BLA meeting, there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug for congenital HI. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16^th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706

12 of 13 Multifamily Properties Now Sold; Proceeds Used to Reduce Debt

Sale of Final Multifamily Property, Premier Apartments, Expected to Close in Q2 2027

VIRGINIA BEACH, Va., Nov. 13, 2026 (GLOBE NEWSWIRE) — AH Realty Trust (NYSE: AHRT) (“AHRT” or the “Company”) today announced it has completed the sale of Greenside Apartments, a 225-unit multifamily property in Charlotte, North Carolina, to affiliates of Harbor Group International, LLC (“HGI”) at the full contract price, with no subsequent adjustment. The Company used the proceeds to further reduce debt.

This closing marks the sale of the 12^th of 13 multifamily properties AH Realty Trust identified for sale as part of its strategic transformation announced in February 2026. The Company has also completed the sale of its general contracting and real estate services business and exited its real estate financing program. Proceeds from these dispositions have enabled AH Realty Trust to reduce its leverage to within its target range of 5.5x–6.5x Net Debt to Adjusted EBITDA.

“When we began this transformation, we committed to shareholders we would sell the multifamily portfolio, exit our non-core businesses and reduce leverage, and we have substantially delivered on each of these objectives. The sale of Greenside is another milestone,” said Shawn Tibbetts, Chairman, President and Chief Executive Officer of AH Realty Trust. “Today, AH Realty Trust is a simpler, stronger, and more focused operator of retail and mixed-use office properties, positioned for long-term value creation.”

The closing of Premier Apartments, the remaining property under contract with affiliates of HGI, is expected to occur in the second quarter of 2027.

About AH Realty Trust
AH Realty Trust (NYSE: AHRT) is a real estate investment trust (“REIT”) with over four decades of experience. The Company owns and operates high-quality retail and mixed-use office assets located primarily in the Mid-Atlantic and Southeastern United States. AH Realty Trust focuses on disciplined capital allocation and value creation for shareholders. For more information visit AHRealtyTrust.com.

Forward-Looking Statements
Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties, and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: the consummation and the timeline for the sale of Premier Apartments to HGI; the application of the proceeds from the sale of the Company’s multifamily assets, including debt reduction; the future prospects of the Company; and the future allocation of the Company’s resources to the Company’s retail and office properties. The forward-looking statements presented herein are based on the Company’s current expectations. For a description of factors that may cause the Company’s actual results or performance to differ from its forward-looking statements, please review the information under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the other documents filed by the Company with the Securities and Exchange Commission from time to time. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in the Company’s expectations with regard thereto, or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

Contact:
Chelsea Forrest
AH Realty Trust
EVP of Investor Relations and Administration
Email: chelsea.forrest@ahrealtytrust.com 

12 of 13 Multifamily Properties Now Sold; Proceeds Used to Reduce Debt

Sale of Final Multifamily Property, Premier Apartments, Expected to Close in Q2 2027

VIRGINIA BEACH, Va., Nov. 13, 2026 (GLOBE NEWSWIRE) — AH Realty Trust (NYSE: AHRT) (“AHRT” or the “Company”) today announced it has completed the sale of Greenside Apartments, a 225-unit multifamily property in Charlotte, North Carolina, to affiliates of Harbor Group International, LLC (“HGI”) at the full contract price, with no subsequent adjustment. The Company used the proceeds to further reduce debt.

This closing marks the sale of the 12^th of 13 multifamily properties AH Realty Trust identified for sale as part of its strategic transformation announced in February 2026. The Company has also completed the sale of its general contracting and real estate services business and exited its real estate financing program. Proceeds from these dispositions have enabled AH Realty Trust to reduce its leverage to within its target range of 5.5x–6.5x Net Debt to Adjusted EBITDA.

“When we began this transformation, we committed to shareholders we would sell the multifamily portfolio, exit our non-core businesses and reduce leverage, and we have substantially delivered on each of these objectives. The sale of Greenside is another milestone,” said Shawn Tibbetts, Chairman, President and Chief Executive Officer of AH Realty Trust. “Today, AH Realty Trust is a simpler, stronger, and more focused operator of retail and mixed-use office properties, positioned for long-term value creation.”

The closing of Premier Apartments, the remaining property under contract with affiliates of HGI, is expected to occur in the second quarter of 2027.

About AH Realty Trust
AH Realty Trust (NYSE: AHRT) is a real estate investment trust (“REIT”) with over four decades of experience. The Company owns and operates high-quality retail and mixed-use office assets located primarily in the Mid-Atlantic and Southeastern United States. AH Realty Trust focuses on disciplined capital allocation and value creation for shareholders. For more information visit AHRealtyTrust.com.

Forward-Looking Statements
Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties, and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: the consummation and the timeline for the sale of Premier Apartments to HGI; the application of the proceeds from the sale of the Company’s multifamily assets, including debt reduction; the future prospects of the Company; and the future allocation of the Company’s resources to the Company’s retail and office properties. The forward-looking statements presented herein are based on the Company’s current expectations. For a description of factors that may cause the Company’s actual results or performance to differ from its forward-looking statements, please review the information under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the other documents filed by the Company with the Securities and Exchange Commission from time to time. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein, to reflect any change in the Company’s expectations with regard thereto, or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

Contact:
Chelsea Forrest
AH Realty Trust
EVP of Investor Relations and Administration
Email: chelsea.forrest@ahrealtytrust.com 

• At the 2026 iCAUR International User Summit, Club Connect, the brand’s global user community program, was officially launched. iCAUR now runs official user clubs across nine countries.
• User co-creation forums and the first cohort of global brand ambassadors have been revealed in sequence: owners are no longer merely consumers, but activity organizers, content creators and product co-creators.
• Club Connect will expand into more countries and regions worldwide. Through localized operations, diverse community events and ongoing brand ambassador recruitment, iCAUR will build a shared user ecosystem alongside its community.

WUHU, China, Nov. 13, 2026 (GLOBE NEWSWIRE) — Held in Wuhu, China from 19 to 23 October, the 2026 iCAUR International User Summit marked the official debut of Club Connect, an interactive hub linking owners around the world. iCAUR currently operates official user clubs in nine countries, with plans to extend this network into more markets by 2027.

For Chery Group’s iCAUR, vehicle handover is not the end of the journey — it is the beginning. Club Connect anchors the ongoing companionship that follows delivery: within this community, owners are more than consumers; they initiate activities, craft content and co-develop products. Shifting global owners from “buying the same car” to “sharing the same ecosystem”, the initiative redefines the bond between iCAUR and its users.

Club Connect Only Has Meaning When Users Come First

Club Connect grew alongside the iCAUR brand. Since its launch, iCAUR has entered over 40 global markets. Its first all-electric boxy SUV, the iCAUR V23, has passed 100,000 units in cumulative global sales. Across international markets, iCAUR users value self-expression, exploratory adventures and peer connection; nearly half personalize and modify their vehicles.

[Creative customized vehicles from global users gathered at the conference venue]

iCAUR recognizes that building great cars is not enough — user priorities must sit at the center. Club Connect seeks to connect global users on every level: honoring individual expression, giving creative ideas a home, and enabling joint creation and shared progress between brand and community. This embodies the spirit of “Make It Yours.” With Future Classic Design, iCAUR delivers timeless vehicles while granting users ample room for self-expression. The same iCAUR model can take distinct forms in different hands, yet users’ desire for personal expression and emotional connection transcends borders. Club Connect unites these scattered aspirations, bringing like-minded people to journey side by side. For owners, purchasing an iCAUR means more than acquiring a vehicle; it unlocks a gateway to fresh experiences.

Handing the Microphone to Users to Capture Their Authentic Voices

Listening to users lies at the heart of Club Connect. The iCAUR User Co-Creation Exchange Session hosted during the summit demonstrated this commitment. Owner representatives from multiple markets sat down with iCAUR leadership, and “how to shape Club Connect” emerged as a core discussion theme. Moving beyond the conventional stage-and-audience format, the session passed the microphone to users. Management responded in real time, and insights and expectations from each market were carefully documented to feed into the global framework for Club Connect.

Meaningful listening must be followed by action. As Club Connect rolls out across more countries and regions, richer community formats will continue to launch. Ongoing refinements to models including the V23, V25 and V27 reflect the same philosophy. At the conference’s all-scenario test-drive camp, user feedback on power, handling and comfort was sent directly to the R&D team, turning real-world owner needs into product design input. Looking ahead, iCAUR will also showcase customized models alongside every new vehicle launch, offering users inspiration for their own modifications.

[Three official iCAUR customized vehicles unveiled at the brand launch]

From earnest listening to globally refined products; from responding to a single user’s request to supporting countless journeys on the road — iCAUR’s core mission remains unchanged: genuine user care bridges gaps and builds lasting trust.

First Global Brand Ambassadors Take the Stage, Putting Users in the Spotlight

At the summit, iCAUR revealed its inaugural group of ten global brand ambassadors, selected from user communities in South Africa, Malaysia, Indonesia, Thailand, the UAE and other international markets. Some have turned their V23 into a trusted companion for weekend rural adventures; others use their vehicle as a mobile photography studio… Each has uncovered the unique charm of owning an iCAUR. By elevating these users to center stage, iCAUR returns the platform to those who know its products best: people who understand the vehicles, possess refined taste, and grasp what fellow owners truly value.

[Ten global brand ambassadors announced at the launch event]

iCAUR holds that future classics are not defined by the brand alone, but co-created with its users. Moving forward, Club Connect will keep recruiting brand ambassadors from global communities, empowering buyers to become participants, witnesses and advocates in the brand’s development.

From celebrating individual user identity to co-building future classics alongside the community, this respect for users has driven iCAUR to break down barriers between brand and owner. As Club Connect expands further across the globe, more owners will connect and travel together within this network. There is every reason to believe that a brand such as iCAUR — one that places users first, listens humbly and serves wholeheartedly — will travel farther and with greater steadiness.                 

About iCAUR

iCAUR is a new energy automotive brand driven by Future Classic Design and technology. Guided by its design philosophy, iCAUR combines classic design elements with modern aesthetics and technology to develop distinctive vehicles for urban mobility and outdoor exploration. With a focus on product innovation and customization, iCAUR offers diverse vehicle choices and personalization options, extending its brand experience through user services and a growing range of user engagements initiatives.

iCAUR’s product portfolio is supported by technologies including i-AWD intelligent electric all-wheel drive and the REEV Golden Range Extender, delivering performance and capability for a range of driving conditions. With a growing presence in more than 40 markets worldwide, iCAUR continues to expand its international business and user engagements, guided by its brand belief: Classic Never Fades.

Serena Wang
Email: wangjieyun2@mychery.com
Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/9d282c40-1c30-4b68-a0fe-ed5eabaa68f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/07f6e8ad-3300-440a-a2b5-ba95df2ee344

https://www.globenewswire.com/NewsRoom/AttachmentNg/814d4356-b2d5-41fe-ab6e-cc5c0b58417a

• At the 2026 iCAUR International User Summit, Club Connect, the brand’s global user community program, was officially launched. iCAUR now runs official user clubs across nine countries.
• User co-creation forums and the first cohort of global brand ambassadors have been revealed in sequence: owners are no longer merely consumers, but activity organizers, content creators and product co-creators.
• Club Connect will expand into more countries and regions worldwide. Through localized operations, diverse community events and ongoing brand ambassador recruitment, iCAUR will build a shared user ecosystem alongside its community.

WUHU, China, Nov. 13, 2026 (GLOBE NEWSWIRE) — Held in Wuhu, China from 19 to 23 October, the 2026 iCAUR International User Summit marked the official debut of Club Connect, an interactive hub linking owners around the world. iCAUR currently operates official user clubs in nine countries, with plans to extend this network into more markets by 2027.

For Chery Group’s iCAUR, vehicle handover is not the end of the journey — it is the beginning. Club Connect anchors the ongoing companionship that follows delivery: within this community, owners are more than consumers; they initiate activities, craft content and co-develop products. Shifting global owners from “buying the same car” to “sharing the same ecosystem”, the initiative redefines the bond between iCAUR and its users.

Club Connect Only Has Meaning When Users Come First

Club Connect grew alongside the iCAUR brand. Since its launch, iCAUR has entered over 40 global markets. Its first all-electric boxy SUV, the iCAUR V23, has passed 100,000 units in cumulative global sales. Across international markets, iCAUR users value self-expression, exploratory adventures and peer connection; nearly half personalize and modify their vehicles.

[Creative customized vehicles from global users gathered at the conference venue]

iCAUR recognizes that building great cars is not enough — user priorities must sit at the center. Club Connect seeks to connect global users on every level: honoring individual expression, giving creative ideas a home, and enabling joint creation and shared progress between brand and community. This embodies the spirit of “Make It Yours.” With Future Classic Design, iCAUR delivers timeless vehicles while granting users ample room for self-expression. The same iCAUR model can take distinct forms in different hands, yet users’ desire for personal expression and emotional connection transcends borders. Club Connect unites these scattered aspirations, bringing like-minded people to journey side by side. For owners, purchasing an iCAUR means more than acquiring a vehicle; it unlocks a gateway to fresh experiences.

Handing the Microphone to Users to Capture Their Authentic Voices

Listening to users lies at the heart of Club Connect. The iCAUR User Co-Creation Exchange Session hosted during the summit demonstrated this commitment. Owner representatives from multiple markets sat down with iCAUR leadership, and “how to shape Club Connect” emerged as a core discussion theme. Moving beyond the conventional stage-and-audience format, the session passed the microphone to users. Management responded in real time, and insights and expectations from each market were carefully documented to feed into the global framework for Club Connect.

Meaningful listening must be followed by action. As Club Connect rolls out across more countries and regions, richer community formats will continue to launch. Ongoing refinements to models including the V23, V25 and V27 reflect the same philosophy. At the conference’s all-scenario test-drive camp, user feedback on power, handling and comfort was sent directly to the R&D team, turning real-world owner needs into product design input. Looking ahead, iCAUR will also showcase customized models alongside every new vehicle launch, offering users inspiration for their own modifications.

[Three official iCAUR customized vehicles unveiled at the brand launch]

From earnest listening to globally refined products; from responding to a single user’s request to supporting countless journeys on the road — iCAUR’s core mission remains unchanged: genuine user care bridges gaps and builds lasting trust.

First Global Brand Ambassadors Take the Stage, Putting Users in the Spotlight

At the summit, iCAUR revealed its inaugural group of ten global brand ambassadors, selected from user communities in South Africa, Malaysia, Indonesia, Thailand, the UAE and other international markets. Some have turned their V23 into a trusted companion for weekend rural adventures; others use their vehicle as a mobile photography studio… Each has uncovered the unique charm of owning an iCAUR. By elevating these users to center stage, iCAUR returns the platform to those who know its products best: people who understand the vehicles, possess refined taste, and grasp what fellow owners truly value.

[Ten global brand ambassadors announced at the launch event]

iCAUR holds that future classics are not defined by the brand alone, but co-created with its users. Moving forward, Club Connect will keep recruiting brand ambassadors from global communities, empowering buyers to become participants, witnesses and advocates in the brand’s development.

From celebrating individual user identity to co-building future classics alongside the community, this respect for users has driven iCAUR to break down barriers between brand and owner. As Club Connect expands further across the globe, more owners will connect and travel together within this network. There is every reason to believe that a brand such as iCAUR — one that places users first, listens humbly and serves wholeheartedly — will travel farther and with greater steadiness.                 

About iCAUR

iCAUR is a new energy automotive brand driven by Future Classic Design and technology. Guided by its design philosophy, iCAUR combines classic design elements with modern aesthetics and technology to develop distinctive vehicles for urban mobility and outdoor exploration. With a focus on product innovation and customization, iCAUR offers diverse vehicle choices and personalization options, extending its brand experience through user services and a growing range of user engagements initiatives.

iCAUR’s product portfolio is supported by technologies including i-AWD intelligent electric all-wheel drive and the REEV Golden Range Extender, delivering performance and capability for a range of driving conditions. With a growing presence in more than 40 markets worldwide, iCAUR continues to expand its international business and user engagements, guided by its brand belief: Classic Never Fades.

Serena Wang
Email: wangjieyun2@mychery.com
Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/9d282c40-1c30-4b68-a0fe-ed5eabaa68f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/07f6e8ad-3300-440a-a2b5-ba95df2ee344

https://www.globenewswire.com/NewsRoom/AttachmentNg/814d4356-b2d5-41fe-ab6e-cc5c0b58417a

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Blossom Gold Inc. (“Blossom” or the “Company”) (TSX: BGAU, OTCQX: BGAUF) is pleased to announce that the U.S. Bureau of Land Management (“BLM”) has approved Notices of Intent (“NOI”) to conduct site investigation activities on the Company’s RBX claims and the Rosebud West area. The RBX claims, located southeast of the Rosebud claim block, are planned to host the Project’s primary infrastructure, including the ore conveyor, secondary and tertiary crushing, agglomeration and processing facilities, and heap leach pad as well as the planned waste rock storage facility. The NOI for Rosebud West is southwest of the Rosebud Claims and encompasses the water well field area where water is expected to be sourced for the Project.

Highlights

• RBX and Rosebud West NOIs approved: These NOIs are required to conduct investigations required for Project processing facilities locations and Project water supply.
• Planned infrastructure investigations: The RBX NOI covers access and condemnation holes, geotechnical test pits, and shallow geotechnical probe holes, over planned locations for Rosebud’s conveying, crushing, heap leach pad, processing facilities and waste rock storage facility.   The Rosebud West NOI allows for the drilling and installation of groundwater monitoring wells as well as test wells in relation to the estimated 5,000 acre foot per annum water supply requirement of the Project.
• Permitting and feasibility inputs: Groundwater and geotechnical data collected under the RBX NOI, together with work in the Well Field Area under the Rosebud West NOI, will support facility design and water supply planning for the Feasibility Study, Federal Plan of Operations and Nevada Reclamation Permit applications being prepared for the Project.

“Receipt of the RBX and West Rosebud NOIs allows us to maintain our critical path for expected, positive Federal and State decisions to commence construction at Rosebud in 2029,” said Rick Winters, Chief Executive Officer of Blossom Gold. “The RBX claims were originally staked for the purpose of processing and infrastructure and we will conduct confirmation drilling to be sure. Rosebud West encompasses our expected primary water supply for the planned mine and processing facilities. We will be drilling monitoring and test wells as one part of our strategy for securing Project water supply. The work on both NOIs will feed directly into permitting and feasibility studies,” added Mr. Winters.

“Collecting site-specific groundwater and geotechnical data on the RBX claims is a critical step on our permitting path,” stated Alan Haslam, VP, Permitting of Blossom Gold. “Baseline hydrogeology and foundation conditions beneath the planned heap leach pad, waste rock storage and processing facilities are core inputs to the Plan of Operations and Nevada Reclamation Permit application we are preparing for submittal to the BLM Black Rock Field Office and the Nevada Division of Environmental Protection, Bureau of Mining Regulation and Reclamation, as well as to the Environmental Impact Statement and Feasibility Study. Approval of the Rosebud West Notice also allows us to advance work in the area where we expect to source the Project’s water. Starting this work now keeps our permitting timeline aligned with the Feasibility Study and keeps us on track for construction authorizations for Rosebud by 2029.”

Figure 1 – RBX and Rosebud West NOIs

Blossom Gold Inc.

Blossom continues to advance the Rosebud Project with surface drilling ongoing, underground infill drilling expected to commence in December and ongoing metallurgical testing with initial column results beginning in December all supporting an updated Mineral Resource Estimate expected the end of Q1 2027. Ongoing permitting, preliminary engineering and design and work under the RBX and Rosebud West NOIs will support the application for the Plan of Operations and initiation of Feasibility Q2 2027.

About Blossom Gold Inc.

Blossom is a Canadian-based precious metals exploration and development company that trades on the TSX under the symbol BGAU and on the OTCQX under the symbol BGAUF. Blossom acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Dino Titaro, P.Geo., a Director of Blossom who is a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

For further information, please contact:

Brandon Throop
Vice President, Corporate Development & Investor Relations
Direct: 1-647-646-7824
Email: bthroop@blossomgold.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements other than statements of historical facts included in this news release constitute forward-looking information, including but not limited to statements regarding the Company’s plans, prospects and business strategies, including its senior leadership team, its core drilling program and advancing the Rosebud Project, permitting and commencing construction, and its vision regarding the Rosebud Project. Terminology such as “plan”, “expect”, “schedule”, “estimate”, “forecast”, “intend”, “anticipate”, “believe”, “may” or “will” and similar expressions identify forward-looking information. By identifying such information in this manner, Blossom is alerting the reader that such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Blossom to be materially different from those expressed or implied by such information. In addition, in connection with the forward-looking information contained in this news release, Blossom has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the inability of Blossom to achieve any one or more of the key catalysts on the timeline expected, or at all, and any changes in the development of the business of Blossom, as well as those risk factors more generally set out in Blossom’s AIF, which is available under Blossom’s profile on SEDAR+ at www.sedarplus.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein. Although Blossom believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information are reasonable, undue reliance should not be placed on such information, and no assurance or guarantee can be given that such forward-looking information will prove to be accurate. The forward-looking information contained in this news release is provided as of the date of this news release, and Blossom does not undertake to update any forward-looking information that is contained or referenced herein, except in accordance with applicable Canadian securities laws.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/043d1636-6a63-4d05-8f0d-6d0165c8eb79

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ad4525f-b657-4d65-ab2b-390c1d380473

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Blossom Gold Inc. (“Blossom” or the “Company”) (TSX: BGAU, OTCQX: BGAUF) is pleased to announce that the U.S. Bureau of Land Management (“BLM”) has approved Notices of Intent (“NOI”) to conduct site investigation activities on the Company’s RBX claims and the Rosebud West area. The RBX claims, located southeast of the Rosebud claim block, are planned to host the Project’s primary infrastructure, including the ore conveyor, secondary and tertiary crushing, agglomeration and processing facilities, and heap leach pad as well as the planned waste rock storage facility. The NOI for Rosebud West is southwest of the Rosebud Claims and encompasses the water well field area where water is expected to be sourced for the Project.

Highlights

• RBX and Rosebud West NOIs approved: These NOIs are required to conduct investigations required for Project processing facilities locations and Project water supply.
• Planned infrastructure investigations: The RBX NOI covers access and condemnation holes, geotechnical test pits, and shallow geotechnical probe holes, over planned locations for Rosebud’s conveying, crushing, heap leach pad, processing facilities and waste rock storage facility.   The Rosebud West NOI allows for the drilling and installation of groundwater monitoring wells as well as test wells in relation to the estimated 5,000 acre foot per annum water supply requirement of the Project.
• Permitting and feasibility inputs: Groundwater and geotechnical data collected under the RBX NOI, together with work in the Well Field Area under the Rosebud West NOI, will support facility design and water supply planning for the Feasibility Study, Federal Plan of Operations and Nevada Reclamation Permit applications being prepared for the Project.

“Receipt of the RBX and West Rosebud NOIs allows us to maintain our critical path for expected, positive Federal and State decisions to commence construction at Rosebud in 2029,” said Rick Winters, Chief Executive Officer of Blossom Gold. “The RBX claims were originally staked for the purpose of processing and infrastructure and we will conduct confirmation drilling to be sure. Rosebud West encompasses our expected primary water supply for the planned mine and processing facilities. We will be drilling monitoring and test wells as one part of our strategy for securing Project water supply. The work on both NOIs will feed directly into permitting and feasibility studies,” added Mr. Winters.

“Collecting site-specific groundwater and geotechnical data on the RBX claims is a critical step on our permitting path,” stated Alan Haslam, VP, Permitting of Blossom Gold. “Baseline hydrogeology and foundation conditions beneath the planned heap leach pad, waste rock storage and processing facilities are core inputs to the Plan of Operations and Nevada Reclamation Permit application we are preparing for submittal to the BLM Black Rock Field Office and the Nevada Division of Environmental Protection, Bureau of Mining Regulation and Reclamation, as well as to the Environmental Impact Statement and Feasibility Study. Approval of the Rosebud West Notice also allows us to advance work in the area where we expect to source the Project’s water. Starting this work now keeps our permitting timeline aligned with the Feasibility Study and keeps us on track for construction authorizations for Rosebud by 2029.”

Figure 1 – RBX and Rosebud West NOIs

Blossom Gold Inc.

Blossom continues to advance the Rosebud Project with surface drilling ongoing, underground infill drilling expected to commence in December and ongoing metallurgical testing with initial column results beginning in December all supporting an updated Mineral Resource Estimate expected the end of Q1 2027. Ongoing permitting, preliminary engineering and design and work under the RBX and Rosebud West NOIs will support the application for the Plan of Operations and initiation of Feasibility Q2 2027.

About Blossom Gold Inc.

Blossom is a Canadian-based precious metals exploration and development company that trades on the TSX under the symbol BGAU and on the OTCQX under the symbol BGAUF. Blossom acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Dino Titaro, P.Geo., a Director of Blossom who is a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

For further information, please contact:

Brandon Throop
Vice President, Corporate Development & Investor Relations
Direct: 1-647-646-7824
Email: bthroop@blossomgold.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements other than statements of historical facts included in this news release constitute forward-looking information, including but not limited to statements regarding the Company’s plans, prospects and business strategies, including its senior leadership team, its core drilling program and advancing the Rosebud Project, permitting and commencing construction, and its vision regarding the Rosebud Project. Terminology such as “plan”, “expect”, “schedule”, “estimate”, “forecast”, “intend”, “anticipate”, “believe”, “may” or “will” and similar expressions identify forward-looking information. By identifying such information in this manner, Blossom is alerting the reader that such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Blossom to be materially different from those expressed or implied by such information. In addition, in connection with the forward-looking information contained in this news release, Blossom has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the inability of Blossom to achieve any one or more of the key catalysts on the timeline expected, or at all, and any changes in the development of the business of Blossom, as well as those risk factors more generally set out in Blossom’s AIF, which is available under Blossom’s profile on SEDAR+ at www.sedarplus.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein. Although Blossom believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information are reasonable, undue reliance should not be placed on such information, and no assurance or guarantee can be given that such forward-looking information will prove to be accurate. The forward-looking information contained in this news release is provided as of the date of this news release, and Blossom does not undertake to update any forward-looking information that is contained or referenced herein, except in accordance with applicable Canadian securities laws.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/043d1636-6a63-4d05-8f0d-6d0165c8eb79

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ad4525f-b657-4d65-ab2b-390c1d380473